New approach to budget impact analysis-ibrutinib in treatment of relapsed/refractory CLL patients in the Czech Republic

Category Primary study
JournalValue in Health
Year 2016
This article has no abstract
Epistemonikos ID: 01b5534cc75793ada8de9e3b4fd7021be6279f78
First added on: Feb 08, 2025